Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T98459 | ||||
Target Name | G2/mitotic-specific cyclin B1 (CCNB1) | ||||
Type of Target |
Patented-recorded |
||||
Drug Potency against Target | 3,4-bis(indol-3-yl)maleimide derivative | Drug Info | IC50 = 4500 nM | [3] | |
AZAKENPAULLONE | Drug Info | IC50 = 2000 nM | [1] | ||
Bisindolylmaleimide-I | Drug Info | IC50 = 19000 nM | [3] | ||
KENPAULLONE | Drug Info | IC50 = 400 nM | [2] | ||
RO-316233 | Drug Info | IC50 = 18000 nM | [3] | ||
Thieno analogue of kenpaullone | Drug Info | IC50 = 600 nM | [1] | ||
References | |||||
REF 1 | 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. | ||||
REF 2 | Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30. | ||||
REF 3 | Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.